Full text

Turn on search term navigation

© Saudi Medical Journal 2019. This work is licensed under the Creative Commons  Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Chronic lymphocytic leukemia (CLL) is an incurable malignant disease of B-lymphocytes characterized by drastically heterogeneous clinical courses. Proteomics is an advanced approach that allows a global profiling of protein expression, providing a valuable chance for the discovery of disease-related proteins. In the last 2 decades, several proteomics studies were conducted on CLL to identify aberrant protein expression underpinning the malignant transformation and progression of the disease. Overall, these studies provided insights into the pathology and prognosis of CLL and reveal protein candidates with the potential to serve as biomarkers and/or therapeutic targets of the tumor. The major findings reported in these studies are discussed here.

Details

Title
Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia
Author
Alsagaby, Suliman A 1 ; Alhumaydhi, Fahad A 1 

 From the Department of Medical Laboratories Sciences (Alsagaby), Faculty of Applied Medical Sciences, Majmaah University, Majmaah, and from the Department of Medical Laboratories (Alhumaydhi), College of Applied Medical Sciences, Qassim University, Buraydah, Kingdom of Saudi Arabia 
Pages
317-327
Publication year
2019
Publication date
Apr 2019
Publisher
Prince Sultan Military Medical City (PSMMC)
ISSN
03795284
e-ISSN
16583175
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2342988287
Copyright
© Saudi Medical Journal 2019. This work is licensed under the Creative Commons  Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.